GSX1 and neoplasm: By integrating tumour purity score (TPS) into the gene expression profile, we proposed a dual therapeutic strategy: one focusing on TME interactions, particularly immune response-related components such as LILRB4, and the other targeting tumour intrinsic cellular mechanisms influenced by gene expression perspective, including transcription factors, such as GSX1 and SOX11.